EHA 2022 | An update on the GIMEMA LAL2116 trial
Sabina Chiaretti
• 12 Jun 2022
Sabina Chiaretti, MD, PhD, Sapienza University of Rome, Rome, Italy, shares some updates from the GIMEMA LAL2116 trial (NCT02744768) and the role of chemotherapy-free regimens in acute lymphoblastic leukemia (ALL). This trial investigated the use of dasatinib and blinatumomab for the treatment of Ph+ ALL, and Dr Chiaretti briefly highlights the promising results obtained, and further discusses some results from an ancillary trial evaluating the long-term follow-up of patients enrolled in GIMEMA LAL2116. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
Disclosures
Amgen, Incyte, Novartis, AbbVie, Gilead.
